AstraZeneca Pharma India gets DCGI nod for Calquence-Acalabrutinib 100mg capsules Medical Dialogues Bureau14 March 2020 12:03 PM ISTAcalabrutinib 100mg capsules are indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).
AstraZeneca India bags DCGI marketing nod for QTERN-once-daily anti-diabetes drug Medical Dialogues Bureau27 Sept 2019 11:54 AM IST26 September 2019: AstraZeneca Pharma India Limited (AstraZeneca India) announced that it has received Import & Market permission for QTERN®...
CDSCO grants approval to AstraZeneca India for Breakthrough Therapy of lung cancer Ruby Khatun Khatun13 Nov 2017 5:39 PM ISTThrough a recent notification, Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Ministry of Health and...